Physician profile
Karen M Pendleton
NPI 1871781666
$989.81
in general payments reported to CMS, 2019-2025
20 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $51.48 · 2021: $190 · 2022: $169 · 2023: $100 · 2024: $209 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $261.59 | 2021-2024 | |
| Incyte Corporation | $167.99 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $95.19 | 2021-2025 | Absorica Ld, Winlevi |
| Revance Therapeutics, INC. | $72.64 | 2025 | Daxxify |
| Ucb, INC. | $47.86 | 2021-2025 | Bimzelx |
| Journey Medical Corporation | $45.44 | 2022-2023 | |
| Leo Pharma INC. | $42.67 | 2024-2025 | Anzupgo, Adbry |
| Almirall LLC | $31.27 | 2021-2022 | |
| Convatec INC. | $27.53 | 2025 | |
| Amgen INC. | $27.27 | 2024 | Otezla |
| Merz North America, INC. | $25.58 | 2020 | |
| Cipher Pharmaceuticals US LLC | $22.42 | 2025 | Spinosad, Natroba |
| Biofrontera INC. | $18.94 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Helsinn Therapeutics (U.S.), INC. | $18.04 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.97 | 2023 | Ycanth |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.14 | 2023 | Seglentis |
| Organogenesis INC. | $14.30 | 2024 | |
| Acelrx Pharmaceuticals, INC. | $14.07 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.58 | 2020 | |
| Vyne Pharmaceuticals INC. | $12.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.